$1.79
0.01[0.56%]
At close: Apr 26
$1.79
0[0.00%]
PreMarket: 8:46AM EDT
Amylyx Pharma
(NASDAQ:AMLX)Amylyx Pharma Stock (NASDAQ:AMLX), Analyst Ratings, Price Targets, Predictions
Amylyx Pharmaceuticals Inc has a consensus price target of $23.55, established from looking at the 41 latest analyst ratings. The last 3 analyst ratings were released from Baird, HC Wainwright & Co., and HC Wainwright & Co. on April 11, 2024, April 11, 2024, and April 8, 2024. With an average price target of $6.33 between Baird, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 253.82% upside for Amylyx Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Baird
HC Wainwright & Co.
Deutsche Bank
Goldman Sachs
Leerink Partners
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Amylyx Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 67.6% | Baird | Joel Beatty | $4 → $3 | Maintains | Neutral | Get Alert |
| 04/11/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 346.93% | HC Wainwright & Co. | Andrew Fein | → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 346.93% | HC Wainwright & Co. | Andrew Fein | $8 → $8 | Maintains | Buy | Get Alert |
| 03/12/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 346.93% | HC Wainwright & Co. | Andrew Fein | $42 → $8 | Maintains | Buy | Get Alert |
| 03/11/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 346.93% | Deutsche Bank | Neena Bitritto-Garg | $36 → $8 | Maintains | Buy | Get Alert |
| 03/11/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 123.46% | Goldman Sachs | Chris Shibutani | $40 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 03/11/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | — | Leerink Partners | Marc Goodman | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/11/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 123.46% | Baird | Joel Beatty | $37 → $4 | Downgrade | Outperform → Neutral | Get Alert |
| 03/08/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | — | Evercore ISI Group | Umer Raffat | — | Downgrade | Outperform → In-Line | Get Alert |
| 03/08/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 1687.71% | Mizuho | Graig Suvannavejh | $27 → $32 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 1967.04% | Baird | Joel Beatty | → $37 | Initiates | → Outperform | Get Alert |
| 12/21/2023 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 1408.38% | Mizuho | Graig Suvannavejh | $46 → $27 | Maintains | Buy | Get Alert |
| 12/12/2023 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 1911.17% | Deutsche Bank | Neena Bitritto-Garg | → $36 | Initiates | → Buy | Get Alert |
| 11/10/2023 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 2134.64% | Goldman Sachs | Chris Shibutani | $46 → $40 | Maintains | Buy | Get Alert |
| 11/10/2023 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 2246.37% | HC Wainwright & Co. | Andrew Fein | $50 → $42 | Maintains | Buy | Get Alert |
| 08/11/2023 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 2693.3% | HC Wainwright & Co. | Andrew Fein | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 2693.3% | HC Wainwright & Co. | Andrew Fein | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 2637.43% | Goldman Sachs | Chris Shibutani | $45 → $49 | Upgrade | Neutral → Buy | Get Alert |
| 05/31/2023 | AMLX | Buy Now | Amylyx Pharma | $1.79 | 2693.3% | HC Wainwright & Co. | Andrew Fein | → $50 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Amylyx Pharma (AMLX)?
The latest price target for Amylyx Pharma (NASDAQ: AMLX) was reported by Baird on April 11, 2024. The analyst firm set a price target for $3.00 expecting AMLX to rise to within 12 months (a possible 67.60% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amylyx Pharma (AMLX)?
The latest analyst rating for Amylyx Pharma (NASDAQ: AMLX) was provided by Baird, and Amylyx Pharma maintained their neutral rating.
When was the last upgrade for Amylyx Pharma (AMLX)?
The last upgrade for Amylyx Pharmaceuticals Inc happened on July 24, 2023 when Goldman Sachs raised their price target to $49. Goldman Sachs previously had a neutral for Amylyx Pharmaceuticals Inc.
When was the last downgrade for Amylyx Pharma (AMLX)?
The last downgrade for Amylyx Pharmaceuticals Inc happened on March 11, 2024 when Goldman Sachs changed their price target from $40 to $4 for Amylyx Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Amylyx Pharma (AMLX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amylyx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amylyx Pharma was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating Amylyx Pharma (AMLX) correct?
While ratings are subjective and will change, the latest Amylyx Pharma (AMLX) rating was a maintained with a price target of $4.00 to $3.00. The current price Amylyx Pharma (AMLX) is trading at is $1.79, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.